Trial Profile
Efficacy of Blinatumomab combined with Dasatinib/Ibrutinib in relapsed acute lymphoblastic leukemia
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Sep 2016
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Dasatinib (Primary) ; Ibrutinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Expanded access; Therapeutic Use
- 13 Sep 2016 New trial record